It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8539 ...

Aurobindo, that last year signed a deal with U.S. drugmaker MSD to manufacture one of their biologics products at its subsidiary Theranym Biologics, has agreed on a contract to roll out a single ...

The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, ...

The US Food and Drug Administration approved the first-ever rapid-acting insulin for reducing blood sugar levels. It calls ...

Comparable efficacy results were observed at week 78 after switching to the biosimilar from the reference product (secondary endpoint). Safety, pharmacokinetic, and immunogenicity data demonstrated ...

South Korea’s Celltrion (Kosdaq: 068270) has announced the US launch of Steqeyma (ustekinumab-stba), a biosimilar to Stelara ...

"Biosimilars increase access to essential therapies ... We sell different types of products and services to both investment professionals and individual investors. These products and services ...

Global Biosimilar Testing and Development Services Market is valued approximately at USD 2.80 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.1% over the forecast ...

FYB202/Otulfi ® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union FYB202/Otulfi ® is now commercially available in both subcutaneous and intravenous ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.